<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788461</url>
  </required_header>
  <id_info>
    <org_study_id>PET-BOOST NSCLC</org_study_id>
    <nct_id>NCT02788461</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy</brief_title>
  <acronym>PET-BOOST</acronym>
  <official_title>A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II trial to assess the efficacy and safety of selective metabolically
      adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving
      definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive
      conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost.
      All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan
      within two weeks prior to starting treatment. The primary outcome is to determine if dose
      escalation to metabolically active tumor subvolumes will reduce local-regional failure rate
      at 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of local-regional failure rate</measure>
    <time_frame>2 years</time_frame>
    <description>Primary outcome of the trial is to determine if dose escalation to metabolically active subvolumes will reduce local-regional failure rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Determine if dose escalation to metabolically active subvolumes will improve progression-free survival at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Determine if dose escalation to metabolically active subvolumes will improve overall survival at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 Toxicity Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Determine if dose escalation to metabolically active subvolumes will increase the rate of grade 3-5 toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life FACT-L</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the quality of life in the two arms using Functional Assessment of Cancer Therapy-Lung (FACT-L) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EQ-5D</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the quality of life in the two arms using EuroQol Quality of Life-5 Dimensions (EQ-5D) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Response Characterization</measure>
    <time_frame>2 years</time_frame>
    <description>Characterize the tumor dose-response relationship in the experimental arm and create a tumor control probability model for local-regional failure at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation Feasibility</measure>
    <time_frame>2 weeks</time_frame>
    <description>Explore the feasibility of adaptive dose escalation based on PET response at week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Use</measure>
    <time_frame>2 years</time_frame>
    <description>Explore the use of Week 0 and Week 2 PET images for prognostication and response assessment for local-regional failure at 2 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy with Integrated Boost Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy with Integrated Boost Dose</intervention_name>
    <description>Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.</description>
    <arm_group_label>Chemoradiotherapy with Integrated Boost Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are at least 18 years old and are able to consent

          -  Patients who will undergo Chemo-RT as primarily modality of treatment

          -  Patients with a primary tumor or node measuring at least 10mm on CT scan

          -  Patients with a PET avid tumor having Standardized Uptake Values (SUV) &gt; 4

          -  Patients with Eastern Cooperative Oncology Group (ECOG) status 0-2 within 4 weeks of
             randomization

        Exclusion Criteria:

          -  Trimodality patients who have surgery as part of curative treatment

          -  Previous radiotherapy to intended treatment volumes

          -  Active invasive malignancy other than lung cancer

          -  Active pregnancy

          -  Poor respiratory function (Forced Expiratory Volume &lt; 1.0 or Diffusing Capacity &lt; 50%
             age-adjusted normal)

          -  ECOG status &gt; 2

          -  Pre-treatment complete blood count/differential showing inadequate bone marrow reserve
             (absolute neutrophil count &lt; 1800 cells/mm3 or platelets &lt; 100 000 cells/mm3 or
             hemoglobin &lt; 90g/L), measured within 4 weeks of registration

          -  AST, ALT or total bilirubin &gt; 2.5 times the upper limit of normal, measured within 4
             weeks of registration

          -  Unintentional weight loss &gt;10% over 3 months within 4 weeks of registration

          -  Severe active co-morbidity defined by:

          -  Significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension,
             unstable angina, myocardial infarction within the last 6 months, uncontrolled
             congestive heart failure, cardiomyopathy with decreased ejection fraction

          -  Transmural myocardial infection requiring intravenous antibiotics at the time of
             registration

          -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
             requiring hospitalization or precluding study therapy within 30 days before
             randomization

          -  Acquired immune deficiency syndrome (AIDS) based on the current Centre for Disease
             Control definition; note, however, that HIV testing is not required for entry into
             this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alex Sun, MD, FRCPC</last_name>
    <phone>416 946 4545</phone>
    <email>alex.sun@rmp.uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Palma, MD, FRCPC</last_name>
    <phone>519-685-8500</phone>
    <email>david.palma@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Palma, MD</last_name>
      <phone>519-685-8500</phone>
      <email>david.palma@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Cancer Centre at Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket,</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojgan Taremi, MD, FRCPC</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>6595</phone_ext>
      <email>mtaremi@southlakeregional.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Sun, MD, FRCPC</last_name>
      <phone>(416) 946-2000</phone>
      <email>alex.sun@rmp.uhn.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ont</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Ashworth, MD, FRCPC</last_name>
      <phone>613-544-2631</phone>
      <phone_ext>8106</phone_ext>
      <email>allison.ashworth@krcc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre, Glen site Cedars Cancer Center</name>
      <address>
        <city>Montreal,</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio L. Faria, MD, PhD</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>36157</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Marianna Perna</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>43191</phone_ext>
      <email>marianna.perna@muhc.mcgill.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHUS - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>14311</phone_ext>
      <email>socouture.chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Ladouceur</last_name>
      <phone>819-346-11101</phone>
      <phone_ext>13250</phone_ext>
      <email>cynthia.ladouceur.ciussse.chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marc É Plourde, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam Bouchard, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy A Turgeon, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G2L 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Dagnault, MD PhD</last_name>
      <phone>1 418-525-4444,</phone>
      <phone_ext>15264</phone_ext>
      <email>anne.dagnault@mail.chuq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Josee Allard;</last_name>
      <phone>(418) 525-4444</phone>
      <phone_ext>16730</phone_ext>
      <email>Josee.Allard@chudequebec.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>David Palma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

